CLAIMS

1. Use of a combination of compounds comprising a PPARα agonist and an ACL inhibitor in the manufacture of a medicament for the prophylaxis and/or treatment of dyslipidemia or cardiovascular disease.

2. The use according to claim 1, wherein the dyslipidemia is hypercholesterolemia or hypertriglyceridemia.

3. The use according to claim 1 or 2, wherein the cardiovascular disease is arteriosclerosis or a cardiovascular event.

4. The use according to any one of claims 1 to 3, wherein the PPARα agonist is (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, or a salt, or a solvate, or a solvate of the salt thereof.

5. The use according to any one of claims 1 to 4, wherein the ACL inhibitor is 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, or a salt, or a solvate, or a solvate of the salt thereof.

6. The use according to any one of claims 1 to 5, wherein the medicament is a combination drug.

7. The use according to any one of claims 1 to 5, wherein the medicament is a kit.